XML 34 R19.htm IDEA: XBRL DOCUMENT
v3.5.0.2

Note 12 - Segment Information | 12 Months Ended
--- | ---
Jun. 30, 2016
Notes to Financial Statements |
Segment Reporting Disclosure [Text Block] | Note 12. Segment Information: The Company has three reportable segments based on the nature of its products; they are Biotechnology, Clinical Controls, and Protein Platforms. The Company’s Biotechnology reporting segment develops, manufactures and sells biotechnology research and diagnostic products world-wide. No customer in the Biotechnology segment accounted for more than 10% of the segments' net sales for the years ended June 30, 2016, 2015, and 2014,. The Company’s Clinical Controls reporting segment develops and manufactures controls and calibrators for sale world-wide. One customer accounted for approximately, 13%, and 14% of Clinical Controls’ net sales during fiscal 2015, and 2014 respectively. One customer did not account for net sales over 10% during 2016. The Company’s Protein Platforms segment develops and commercializes proprietary systems and consumables for protein analysis. This segment was formed from the fiscal 2015 acquisitions of ProteinSimple and CyVek. No customer in the Protein Platforms segment accounted for more than 10% of the segments net sales for the years ended June 30, 2016 and 2015. There are no concentrations of business transacted with a particular customer or supplier or concentrations of revenue from a particular product or geographic area that would severely impact the Company in the near term. Following is financial information relating to the operating segments (in thousands):
|  | Year Ended June 30, |
|  | 201 6 |  |  | 201 5 |  |  | 201 4 |
External sales |  |  |  |  |  |  |  |  |  |  |  |
Biotechnology |  | $ | 317,340 |  |  | $ | 308,437 |  |  | $ | 285,142 |
Clinical Controls |  |  | 104,484 |  |  |  | 77,866 |  |  |  | 72,621 |
Protein Platforms |  |  | 77,324 |  |  |  | 66,249 |  |  |  | 0 |
Inter segment |  |  | (125 | ) |  |  | (306 | ) |  |  | 0 |
Consolidated net sales |  | $ | 499,023 |  |  | $ | 452,246 |  |  | $ | 357,763 |
|  | Year Ended June 30, |
|  | 201 6 |  |  | 201 5 |  |  | 201 4 |
Operating Income |  |  |  |  |  |  |  |  |  |  |  |
Biotechnology |  | $ | 168,613 |  |  | $ | 165,226 |  |  | $ | 162,621 |
Clinical Controls |  |  | 30,412 |  |  |  | 23,981 |  |  |  | 22,976 |
Protein Platforms |  |  | 3,592 |  |  |  | 4,469 |  |  |  | 0 |
Segment operating income |  |  | 202,617 |  |  |  | 193,676 |  |  |  | 185,597 |
Costs recognized upon sale of acquired inventory |  |  | (5,431 | ) |  |  | (6,952 | ) |  |  | (7,480 | )
Amortization of intangibles |  |  | (29,395 | ) |  |  | (26,169 | ) |  |  | (10,276 | )
Stock based compensation |  |  | (9,430 | ) |  |  | (5,957 | ) |  |  | (3,523 | )
Acquisition related expenses |  |  | (2,761 | ) |  |  | (4,519 | ) |  |  | (2,247 | )
Corporate general, selling and administrative expenses |  |  | (5,007 | ) |  |  | (3,056 | ) |  |  | (2,321 | )
Consolidated operating income |  | $ | 150,593 |  |  | $ | 147,023 |  |  | $ | 159,750 |
Goodwill |  |  |  |  |  |  |  |  |  |  |  |
Biotechnology |  | $ | 105,380 |  |  | $ | 115,198 |  |  | $ | 90,872 |
Clinical Controls |  |  | 106,692 |  |  |  | 60,601 |  |  |  | 60,601 |
Protein Platforms |  |  | 218,810 |  |  |  | 214,839 |  |  |  | 0 |
Consolidated goodwill |  | $ | 430,882 |  |  | $ | 390,638 |  |  | $ | 151,473 |
Intangible assets, net |  |  |  |  |  |  |  |  |  |  |  |
Biotechnology |  | $ | 57,199 |  |  | $ | 68,777 |  |  | $ | 53,778 |
Clinical Controls |  |  | 86,736 |  |  |  | 49,130 |  |  |  | 54,998 |
Protein Platforms |  |  | 166,589 |  |  |  | 174,932 |  |  |  | 0 |
Consolidated intangible assets, net |  | $ | 310,524 |  |  | $ | 292,839 |  |  | $ | 108,776 |
Assets |  |  |  |  |  |  |  |  |  |  |  |
Biotechnology |  | $ | 387,470 |  |  | $ | 430,524 |  |  | $ | 674,854 |
Clinical Controls |  |  | 212,649 |  |  |  | 74,954 |  |  |  | 66,072 |
Protein Platforms |  |  | 440,343 |  |  |  | 444,899 |  |  |  | 0 |
Segment assets |  |  | 1,040,462 |  |  |  | 950,378 |  |  |  | 740,917 |
Corporate cash and available- for- sale investments |  |  | 31,255 |  |  |  | 52,800 |  |  |  | 60,142 |
Corporate property and equipment |  |  | 56,195 |  |  |  | 58,270 |  |  |  | 60,350 |
Corporate, other |  |  | 1,669 |  |  |  | 1,912 |  |  |  | 1,082 |
Consolidated assets |  | $ | 1,129,581 |  |  | $ | 1,063,360 |  |  | $ | 862,491 |
Depreciation and amortization |  |  |  |  |  |  |  |  |  |  |  |
Biotechnology |  | $ | 14,196 |  |  | $ | 13,820 |  |  | $ | 10,879 |
Clinical Controls |  |  | 10,462 |  |  |  | 7,963 |  |  |  | 7,205 |
Protein Platforms |  |  | 16,027 |  |  |  | 13,364 |  |  |  | 0 |
Segment depreciation and amortization |  |  | 40,685 |  |  |  | 35,147 |  |  |  | 18,084 |
Corporate |  |  | 2,079 |  |  |  | 2,079 |  |  |  | 1,091 |
Consolidated depreciation and amortization |  | $ | 42,764 |  |  | $ | 37,226 |  |  | $ | 19,175 |
Capital purchases |  |  |  |  |  |  |  |  |  |  |  |
Biotechnology |  | $ | 14,295 |  |  | $ | 9,794 |  |  | $ | 4,157 |
Clinical Controls |  |  | 1,780 |  |  |  | 1,932 |  |  |  | 5,687 |
Protein Platforms |  |  | 823 |  |  |  | 8,179 |  |  |  |  |
Segment capital purchases |  |  | 16,898 |  |  |  | 19,905 |  |  |  | 9,844 |
Corporate |  |  | 0 |  |  |  | 0 |  |  |  | 3,977 |
Consolidated capital purchases |  | $ | 16,898 |  |  | $ | 19,905 |  |  | $ | 13,821 |
The other reconciling items include the results of unallocated corporate expenses and the Company’s share of gain (losses) from its equity method investees. Following is financial information relating to geographic areas (in thousands):
|  | Year Ended June 30, |  |
|  | 201 6 |  |  | 201 5 |  |  | 201 4 |  |
External sales |  |  |  |  |  |  |  |  |  |  |  |  |
United States |  | $ | 283,270 |  |  | $ | 245,217 |  |  | $ | 190,359 |  |
U.K. |  |  | 88,680 |  |  |  | 68,055 |  |  |  | 55,144 |  |
Other Europe |  |  | 51,047 |  |  |  | 66,022 |  |  |  | 42,013 |  |
China |  |  | 27,205 |  |  |  | 26,105 |  |  |  | 18,878 |  |
Other Asia |  |  | 24,809 |  |  |  | 23,806 |  |  |  | 32,704 |  |
Rest of world |  |  | 24,012 |  |  |  | 23,041 |  |  |  | 18,665 |  |
Total external sales |  | $ | 499,023 |  |  | $ | 452,246 |  |  | $ | 357,763 |  |
Long-lived assets |  |  |  |  |  |  |  |  |  |  |  |  |
United States and Canada |  | $ | 118,027 |  |  | $ | 119,075 |  |  | $ | 109,790 |  |
Europe |  |  | 14,423 |  |  |  | 11,239 |  |  |  | 8,340 |  |
China |  |  | 1,109 |  |  |  | 1,286 |  |  |  | 678 |  |
Total long-lived assets |  | $ | 133,559 |  |  | $ | 131,600 |  |  | $ | 118,808 |  |
External sales are attributed to countries based on the location of the customer or distributor. Long-lived assets are comprised of land, buildings and improvements and equipment, net of accumulated depreciation and other assets.

X
- References No definition available. + Details
Name: | us-gaap_DisclosureTextBlockAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 34 -URI http://asc.fasb.org/extlink&oid=68060357&loc=d3e8981-108599 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 41 -URI http://asc.fasb.org/extlink&oid=68060357&loc=d3e9038-108599 Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 33 -URI http://asc.fasb.org/extlink&oid=68060357&loc=d3e8971-108599 Reference 4: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 12 -URI http://asc.fasb.org/extlink&oid=68060357&loc=d3e8595-108599 Reference 5: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=68060357&loc=d3e8380-108599 Reference 6: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 32 -URI http://asc.fasb.org/extlink&oid=68060357&loc=d3e8933-108599 Reference 7: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 26 -URI http://asc.fasb.org/extlink&oid=68060357&loc=d3e8844-108599 Reference 8: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 35 -URI http://asc.fasb.org/extlink&oid=68060357&loc=d3e8984-108599 Reference 9: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 40 -URI http://asc.fasb.org/extlink&oid=68060357&loc=d3e9031-108599 Reference 10: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 42 -URI http://asc.fasb.org/extlink&oid=68060357&loc=d3e9054-108599 Reference 11: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 10 -URI http://asc.fasb.org/extlink&oid=68060357&loc=d3e8538-108599 Reference 12: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 29 -URI http://asc.fasb.org/extlink&oid=68060357&loc=d3e8864-108599 Reference 13: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 31 -URI http://asc.fasb.org/extlink&oid=68060357&loc=d3e8924-108599 Reference 14: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 30 -URI http://asc.fasb.org/extlink&oid=68060357&loc=d3e8906-108599 + Details
Name: | us-gaap_SegmentReportingDisclosureTextBlock
Namespace Prefix: | us-gaap_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration